230 related articles for article (PubMed ID: 22951365)
1. Oral delivery of anticancer drugs I: general considerations.
Mazzaferro S; Bouchemal K; Ponchel G
Drug Discov Today; 2013 Jan; 18(1-2):25-34. PubMed ID: 22951365
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of anticancer drugs III: formulation using drug delivery systems.
Mazzaferro S; Bouchemal K; Ponchel G
Drug Discov Today; 2013 Jan; 18(1-2):99-104. PubMed ID: 22981667
[TBL] [Abstract][Full Text] [Related]
3. Oral delivery of anticancer drugs II: the prodrug strategy.
Mazzaferro S; Bouchemal K; Ponchel G
Drug Discov Today; 2013 Jan; 18(1-2):93-8. PubMed ID: 22960308
[TBL] [Abstract][Full Text] [Related]
4. Oral delivery of anticancer drugs: challenges and opportunities.
Thanki K; Gangwal RP; Sangamwar AT; Jain S
J Control Release; 2013 Aug; 170(1):15-40. PubMed ID: 23648832
[TBL] [Abstract][Full Text] [Related]
5. Delivery of anticancer drugs.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
[TBL] [Abstract][Full Text] [Related]
6. Physicians' preferences for prescribing oral and intravenous anticancer drugs: a Discrete Choice Experiment.
Benjamin L; Cotté FE; Philippe C; Mercier F; Bachelot T; Vidal-Trécan G
Eur J Cancer; 2012 Apr; 48(6):912-20. PubMed ID: 22033327
[TBL] [Abstract][Full Text] [Related]
7. Anticancer oral therapy: emerging related issues.
Banna GL; Collovà E; Gebbia V; Lipari H; Giuffrida P; Cavallaro S; Condorelli R; Buscarino C; Tralongo P; Ferraù F
Cancer Treat Rev; 2010 Dec; 36(8):595-605. PubMed ID: 20570443
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Advances in oral delivery of anti-cancer prodrugs.
Jain AK; Jain S
Expert Opin Drug Deliv; 2016 Dec; 13(12):1759-1775. PubMed ID: 27292717
[TBL] [Abstract][Full Text] [Related]
10. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
12. Nanoscale delivery systems for multiple drug combinations in cancer.
Cao Y; Wang B; Lou D; Wang Y; Hao S; Zhang L
Future Oncol; 2011 Nov; 7(11):1347-57. PubMed ID: 22044207
[TBL] [Abstract][Full Text] [Related]
13. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
Lam MS
Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
[TBL] [Abstract][Full Text] [Related]
14. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.
Reddy LH; Bazile D
Adv Drug Deliv Rev; 2014 May; 71():34-57. PubMed ID: 24184489
[TBL] [Abstract][Full Text] [Related]
15. Oral Delivery of Anticancer Agents Using Nanoparticulate Drug Delivery System.
Mathur P; Rawal S; Patel B; Patel MM
Curr Drug Metab; 2019; 20(14):1132-1140. PubMed ID: 31589119
[TBL] [Abstract][Full Text] [Related]
16. Novel metal-based anticancer drugs: a new challenge in drug delivery.
Lainé AL; Passirani C
Curr Opin Pharmacol; 2012 Aug; 12(4):420-6. PubMed ID: 22609113
[TBL] [Abstract][Full Text] [Related]
17. Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.
Krishnaiah YS; Khan MA
Pharm Dev Technol; 2012; 17(5):521-40. PubMed ID: 22681390
[TBL] [Abstract][Full Text] [Related]
18. Does the targeted delivery of theranostic carbon nanotubes have potential as a valid anticancer strategy?
Das M
Ther Deliv; 2014 Jan; 5(1):1-5. PubMed ID: 24341809
[No Abstract] [Full Text] [Related]
19. [Target selectivity of anticancer drugs].
Fattoruso SI; Di Lauro L; Conti F; Amodio A; Lopez M
Clin Ter; 2008; 159(3):189-206. PubMed ID: 18594750
[TBL] [Abstract][Full Text] [Related]
20. Emerging integrated nanohybrid drug delivery systems to facilitate the intravenous-to-oral switch in cancer chemotherapy.
Luo C; Sun J; Du Y; He Z
J Control Release; 2014 Feb; 176():94-103. PubMed ID: 24389337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
